How are we creating fluoroquinolone-resistant tuberculosis?
Bernardo
John
J
Yew
Wing Wai
WW
D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy; D015897:Comorbidity; D004305:Dose-Response Relationship, Drug; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D019348:Empiricism; D024841:Fluoroquinolones / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D017410:Practice Guidelines as Topic; D019233:Retreatment; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy*
D000995:Antitubercular Agents; D024841:Fluoroquinolones